Skip to main content
Erschienen in: The Cerebellum 4/2012

01.12.2012

The Ever Expanding Spinocerebellar Ataxias. Editorial

verfasst von: Antoni Matilla-Dueñas

Erschienen in: The Cerebellum | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The spinocerebellar ataxias (SCAs) are a clinically, genetically, and neuropathologically heterogeneous group of neurological disorders defined by variable degrees of cerebellar ataxia often accompanied by additional cerebellar and non-cerebellar symptoms that, in many cases, defy differentiation based on clinical characterisation alone. The clinical symptoms are triggered by neurodegeneration of the cerebellum and its relay connexions. The current identification of at least 43 SCA subtypes and the causative molecular defects in 27 of them refine the clinical diagnosis, provide molecular testing of at risk, a/pre-symptomatic, prenatal or pre-implantation and facilitate genetic counselling. The recent discovery of new causative SCA genes along with the respective scientific advances is uncovering high complexity and altered molecular pathways involved in the mechanisms by which the mutant gene products cause pathogenesis. Fortunately, the intensive ongoing clinical and neurogenetic research together with the applied molecular approaches is sure to yield scientific advances that will be translated into developing effective treatments for the spinocerebellar ataxias and other similar neurological conditions.
Literatur
1.
Zurück zum Zitat Matilla-Dueñas A, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain. 2006;129:1357–70.CrossRef Matilla-Dueñas A, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain. 2006;129:1357–70.CrossRef
2.
Zurück zum Zitat Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885–94.PubMedCrossRef Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885–94.PubMedCrossRef
3.
Zurück zum Zitat Matilla-Dueñas A, Sanchez I, Corral-Juan M, Davalos A, Alvarez R, Latorre P. Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. Cerebellum. 2010;9:148–66.PubMedCrossRef Matilla-Dueñas A, Sanchez I, Corral-Juan M, Davalos A, Alvarez R, Latorre P. Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. Cerebellum. 2010;9:148–66.PubMedCrossRef
4.
Zurück zum Zitat Matilla-Dueñas A. Machado–Joseph disease and other rare spinocerebellar ataxias. In: Ahmad S, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 172–88. Matilla-Dueñas A. Machado–Joseph disease and other rare spinocerebellar ataxias. In: Ahmad S, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 172–88.
5.
Zurück zum Zitat Matilla-Dueñas A, Corral-Juan M, Volpini V, Sanchez I. The spinocerebellar ataxias: clinical aspects and molecular genetics. In: Ahmad SI, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 351–74. Matilla-Dueñas A, Corral-Juan M, Volpini V, Sanchez I. The spinocerebellar ataxias: clinical aspects and molecular genetics. In: Ahmad SI, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 351–74.
6.
Zurück zum Zitat McKusick V (2010) Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute of Genetic Medicine Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD McKusick V (2010) Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute of Genetic Medicine Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD
7.
Zurück zum Zitat Pagon RA, Bird TC, Dolan CR, Stephenson DA. Gene reviews [internet]. Seattle: University of Washington; 1993–2010. Pagon RA, Bird TC, Dolan CR, Stephenson DA. Gene reviews [internet]. Seattle: University of Washington; 1993–2010.
8.
Zurück zum Zitat Klockgether T. The clinical diagnosis of autosomal dominant spinocerebellar ataxias. Cerebellum. 2008;7:101–5.PubMedCrossRef Klockgether T. The clinical diagnosis of autosomal dominant spinocerebellar ataxias. Cerebellum. 2008;7:101–5.PubMedCrossRef
9.
Zurück zum Zitat Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan—a population-based epidemiological study. Cerebellum. 2008;7:189–97.PubMedCrossRef Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan—a population-based epidemiological study. Cerebellum. 2008;7:189–97.PubMedCrossRef
10.
Zurück zum Zitat Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain J Neurol. 2009;132:1577–88.CrossRef Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain J Neurol. 2009;132:1577–88.CrossRef
11.
Zurück zum Zitat Velazquez Perez L, Cruz GS, Santos Falcon N, Almaguer Mederos LE, Escalona Batallan K, Rodriguez Labrada R, et al. Molecular epidemiology of spinocerebellar ataxias in Cuba: insights into SCA2 founder effect in Holguin. Neurosci Lett. 2009;454:157–60.PubMedCrossRef Velazquez Perez L, Cruz GS, Santos Falcon N, Almaguer Mederos LE, Escalona Batallan K, Rodriguez Labrada R, et al. Molecular epidemiology of spinocerebellar ataxias in Cuba: insights into SCA2 founder effect in Holguin. Neurosci Lett. 2009;454:157–60.PubMedCrossRef
12.
Zurück zum Zitat Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717–20.PubMedCrossRef Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717–20.PubMedCrossRef
13.
Zurück zum Zitat Schmitz-Hubsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology. 2011;74:678–84.CrossRef Schmitz-Hubsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology. 2011;74:678–84.CrossRef
14.
Zurück zum Zitat Schmitz-Hubsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology. 2008;71:982–9.PubMedCrossRef Schmitz-Hubsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology. 2008;71:982–9.PubMedCrossRef
15.
Zurück zum Zitat Chan E, Charles P, Ribai P, Goizet C, Marelli C, Vincitorio CM, et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov Disord. 2011;26:534–8.PubMedCrossRef Chan E, Charles P, Ribai P, Goizet C, Marelli C, Vincitorio CM, et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov Disord. 2011;26:534–8.PubMedCrossRef
16.
Zurück zum Zitat Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology. 2011;77(11):1035–41.PubMedCrossRef Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology. 2011;77(11):1035–41.PubMedCrossRef
17.
Zurück zum Zitat Orr H, M-y C, Banfi S, Kwiatkowski Jr TJ, Servadio A, Beaudet AL, et al. Expansion of an unstable trinucleotide (CAG) repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4:221–6.PubMedCrossRef Orr H, M-y C, Banfi S, Kwiatkowski Jr TJ, Servadio A, Beaudet AL, et al. Expansion of an unstable trinucleotide (CAG) repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4:221–6.PubMedCrossRef
18.
Zurück zum Zitat Kobayashi H, Abe K, Matsuura T, Ikeda Y, Hitomi T, Akechi Y, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet. 2011;89:121–30.PubMedCrossRef Kobayashi H, Abe K, Matsuura T, Ikeda Y, Hitomi T, Akechi Y, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet. 2011;89:121–30.PubMedCrossRef
19.
Zurück zum Zitat Sequeiros J, Martindale J, Seneca S. EMQN Best Practice Guidelines for molecular genetic testing of SCAs. Eur J Hum Genet. 2010;18:1173–6.PubMedCrossRef Sequeiros J, Martindale J, Seneca S. EMQN Best Practice Guidelines for molecular genetic testing of SCAs. Eur J Hum Genet. 2010;18:1173–6.PubMedCrossRef
20.
Zurück zum Zitat Sequeiros J, Seneca S, Martindale J. Consensus and controversies in best practices for molecular genetic testing of spinocerebellar ataxias. Eur J Hum Genet. 2010;18:1188–95.PubMedCrossRef Sequeiros J, Seneca S, Martindale J. Consensus and controversies in best practices for molecular genetic testing of spinocerebellar ataxias. Eur J Hum Genet. 2010;18:1188–95.PubMedCrossRef
21.
23.
Zurück zum Zitat Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, Carrillo-Fumero R. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 2009;24:1111–24.PubMedCrossRef Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, Carrillo-Fumero R. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 2009;24:1111–24.PubMedCrossRef
24.
Zurück zum Zitat Goizet C, Lesca G, Durr A. Presymptomatic testing in Huntington’s disease and autosomal dominant cerebellar ataxias. Neurology. 2002;59:1330–6.PubMedCrossRef Goizet C, Lesca G, Durr A. Presymptomatic testing in Huntington’s disease and autosomal dominant cerebellar ataxias. Neurology. 2002;59:1330–6.PubMedCrossRef
25.
Zurück zum Zitat Watson MJ. Systematic review of the effectiveness of physiotherapy for cerebellar dysfunction. Clin Rehabil. 2009;23:764–5.PubMedCrossRef Watson MJ. Systematic review of the effectiveness of physiotherapy for cerebellar dysfunction. Clin Rehabil. 2009;23:764–5.PubMedCrossRef
26.
Zurück zum Zitat Ilg W, Synofzik M, Brotz D, Burkard S, Giese MA, Schols L. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology. 2009;73:1823–30.PubMedCrossRef Ilg W, Synofzik M, Brotz D, Burkard S, Giese MA, Schols L. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology. 2009;73:1823–30.PubMedCrossRef
27.
Zurück zum Zitat Missaoui B, Thoumie P. How far do patients with sensory ataxia benefit from so-called “proprioceptive rehabilitation”? Neurophysiol Clin. 2009;39:229–33.PubMedCrossRef Missaoui B, Thoumie P. How far do patients with sensory ataxia benefit from so-called “proprioceptive rehabilitation”? Neurophysiol Clin. 2009;39:229–33.PubMedCrossRef
28.
29.
Zurück zum Zitat Matilla-Dueñas A. Machado–Joseph disease and other rare spinocerebellar ataxias. In: Ahmad S, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 172–88. Matilla-Dueñas A. Machado–Joseph disease and other rare spinocerebellar ataxias. In: Ahmad S, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 172–88.
30.
Zurück zum Zitat Matilla-Dueñas A, Corral-Juan M, Volpini V, Sanchez I. The spinocerebellar ataxias: clinical aspects and molecular genetics. In: Ahmad SI, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 351–74. Matilla-Dueñas A, Corral-Juan M, Volpini V, Sanchez I. The spinocerebellar ataxias: clinical aspects and molecular genetics. In: Ahmad SI, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 351–74.
31.
Zurück zum Zitat Matilla-Dueñas A, Serrano C, Alvarez R, Ivánovic-Barbeito YP, Latorre P, Genís D. Novel therapeutic challenges in cerebellar diseases. In: Manto M, Gruol DL, Schmahmann JD, Koibuchi N, Rossi F, editors. Handbook of the cerebellum and cerebellar disorders. New York: Springer; 2012. Matilla-Dueñas A, Serrano C, Alvarez R, Ivánovic-Barbeito YP, Latorre P, Genís D. Novel therapeutic challenges in cerebellar diseases. In: Manto M, Gruol DL, Schmahmann JD, Koibuchi N, Rossi F, editors. Handbook of the cerebellum and cerebellar disorders. New York: Springer; 2012.
32.
Zurück zum Zitat Subramony SH. Overview of autosomal dominant ataxias. In: Subramony SH, Dürr A, editors. Ataxic disorders. Handbook of clinical neurology, vol. 103. Edinburgh: Elsevier; 2012. 3rd series. Subramony SH. Overview of autosomal dominant ataxias. In: Subramony SH, Dürr A, editors. Ataxic disorders. Handbook of clinical neurology, vol. 103. Edinburgh: Elsevier; 2012. 3rd series.
Metadaten
Titel
The Ever Expanding Spinocerebellar Ataxias. Editorial
verfasst von
Antoni Matilla-Dueñas
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
The Cerebellum / Ausgabe 4/2012
Print ISSN: 1473-4222
Elektronische ISSN: 1473-4230
DOI
https://doi.org/10.1007/s12311-012-0376-4

Weitere Artikel der Ausgabe 4/2012

The Cerebellum 4/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.